Arrowhead Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 7,512 put options on the company. This represents an increase of approximately 1,016% compared to the average daily volume of 673 put options.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 51,425 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $15.07, for a total transaction of $774,974.75. Following the completion of the sale, the chief executive officer now directly owns 4,062,377 shares of the company’s stock, valued at $61,220,021.39. This represents a 1.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 276,839 shares of company stock worth $4,054,176 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Large investors have recently made changes to their positions in the stock. World Investment Advisors LLC raised its stake in Arrowhead Pharmaceuticals by 3.8% in the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after purchasing an additional 700 shares during the last quarter. Xponance Inc. raised its position in shares of Arrowhead Pharmaceuticals by 4.5% in the fourth quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company’s stock valued at $327,000 after buying an additional 744 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 2.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company’s stock valued at $714,000 after buying an additional 803 shares during the period. ADAR1 Capital Management LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 10.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 1,195 shares during the period. Finally, Van ECK Associates Corp boosted its position in Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,250 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $12.08 on Tuesday. The firm has a market capitalization of $1.66 billion, a PE ratio of -2.34 and a beta of 0.99. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $30.41. The firm’s 50-day simple moving average is $15.12 and its 200 day simple moving average is $18.55. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, equities research analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ARWR shares. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. B. Riley reiterated a “buy” rating and set a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $41.44.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.